| Sex | |
| Male | 39 (49%) |
| Female | 40 (51%) |
| Median age, y (range) | 81.6 (75-95) |
| 65% > 80 y | |
| Stage (Ann Arbor) | |
| I (bulky) | 1 (1%) |
| II | 14 (18%) |
| III | 17 (22%) |
| IV | 47 (59%) |
| Age-adjusted IPI risk score | |
| Low risk (0) | 8 (10%) |
| Low-intermediate risk (1) | 28 (35%) |
| High-intermediate risk (2) | 29 (37%) |
| High risk (3) | 14 (17%) |
| COO (centralized IHC: Hans10 ) | |
| Non-GCB | 45 (57%) |
| GCB | 34 (43%) |
| Double expressor | 26 (33%) |
| CIRS-G | |
| <6 | 42 (53%) |
| ≥6 | 37 (47%) |
| ECOG performance status score | |
| 0/1 | 60 (76%) |
| ≥2 | 19 (24%) |
| Falls in the past 6 mo | |
| Nil | 43 (54%) |
| Falls | 31 (39%) |
| Missing | 5 (6%) |
| Albumin | |
| Normal (>35 mg/L) | 43 (54%) |
| Low (≤35 mg/L) | 36 (46%) |
| Timed up-and-go score | |
| Normal (≤12 s) | 26 (33%) |
| Abnormal (>12 s) | 46 (58%) |
| Missing | 7 (9%) |
| Follow-up, mo (range) | |
| Median | 35.5 (0.2-71.7) |
| Sex | |
| Male | 39 (49%) |
| Female | 40 (51%) |
| Median age, y (range) | 81.6 (75-95) |
| 65% > 80 y | |
| Stage (Ann Arbor) | |
| I (bulky) | 1 (1%) |
| II | 14 (18%) |
| III | 17 (22%) |
| IV | 47 (59%) |
| Age-adjusted IPI risk score | |
| Low risk (0) | 8 (10%) |
| Low-intermediate risk (1) | 28 (35%) |
| High-intermediate risk (2) | 29 (37%) |
| High risk (3) | 14 (17%) |
| COO (centralized IHC: Hans10 ) | |
| Non-GCB | 45 (57%) |
| GCB | 34 (43%) |
| Double expressor | 26 (33%) |
| CIRS-G | |
| <6 | 42 (53%) |
| ≥6 | 37 (47%) |
| ECOG performance status score | |
| 0/1 | 60 (76%) |
| ≥2 | 19 (24%) |
| Falls in the past 6 mo | |
| Nil | 43 (54%) |
| Falls | 31 (39%) |
| Missing | 5 (6%) |
| Albumin | |
| Normal (>35 mg/L) | 43 (54%) |
| Low (≤35 mg/L) | 36 (46%) |
| Timed up-and-go score | |
| Normal (≤12 s) | 26 (33%) |
| Abnormal (>12 s) | 46 (58%) |
| Missing | 7 (9%) |
| Follow-up, mo (range) | |
| Median | 35.5 (0.2-71.7) |
CIRS-G, cumulative illness rating scale for geriatrics; GCB, germinal center B-cell–like; IPI, International Prognostic Index.